Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications

There are incredible breakthroughs being made right now by life sciences companies, which are exploring and developing new compounds with the potential to transform mental health treatment. But new drugs are just part of the solution.

We continue our look back at the heritage of the Beckley Foundation’s ground-breaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnership. This latest instalment of the Science Explained series examines the link between the acute psychedelic experience and longer-term changes.

Beckley Psytech’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.

From magic mushrooms to ketamine, psychedelic drugs are having a serious heyday across the planet. Currently seeing considerable interest and acceptance by the public to treat emotional distress, the so-called third wave of psychedelics is cresting. And with that swelling attention is the creation of the essential machinery to support the new medical model — including consistent protocols and training preparation for clinicians.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Q&A with Beckley Psytech CEO Cosmo Feilding Mellen

Our latest series looks at the heritage of the Beckley Foundation’s groundbreaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnership.

Part Two: Animals In a two-part blog series Beckley Psytech research scientist Anya Ermakova explores the history of indigenous use of 5-MeO-DMT, the psychedelic agent that is the focus of our lead research programme. In part one she looked at plants containing 5-MeO-DMT; this blog focuses on animals and, in particular, the Sonoran Desert Toad, where the compound occurs naturally.